Decisions about prostate cancer screening in managed care

Area of Science:

• Oncology
• Health Services Research
• Medical Ethics

Background:

• Traditional biomedical models focus on disease diagnosis and treatment metrics.
• Prostate cancer screening and treatment success are often measured by recurrence rates.
• Many men diagnosed with prostate cancer may die from other causes, with treatments impacting quality of life.

Purpose of the Study:

• To contrast the traditional biomedical model with an outcomes model for prostate cancer.
• To illustrate differences in approach regarding prostate cancer screening and treatment.
• To advocate for shared decision-making in prostate cancer management.

Main Methods:

• Literature review and conceptual analysis.
• Comparison of two distinct healthcare models: biomedical vs. outcomes.
• Application of models to prostate cancer screening and treatment decisions.

Main Results:

• The biomedical model prioritizes diagnosis and disease status.
• The outcomes model emphasizes life expectancy and health-related quality of life.
• Treatment for prostate cancer may not always improve survival but can significantly affect quality of life.

Conclusions:

• The outcomes model suggests that prostate cancer screening and treatment decisions should involve informed patients and physicians.
• Shared decision-making is crucial for aligning care with individual patient values and life expectancy.
• A shift towards an outcomes-focused approach can lead to more patient-centered prostate cancer management.